Introduction
Diffuse large B-cell lymphomas (DLBCLs) are the most common lymphoid neoplasms, accounting for ϳ 30% to 40% of all nonHodgkin lymphomas. The introduction of rituximab (R) to the polychemotherapy combination of CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) 1 has significantly improved the outcome of all subgroups of patients. [2] [3] [4] [5] [6] Mechanisms of action of rituximab include direct induction of apoptosis, [7] [8] [9] chemosensitization of tumor cells to the cytotoxic effects of chemotherapy, complement-dependent cellular cytotoxicity, [10] [11] [12] and antibody-dependent cellular cytotoxicity, 11 of which the latter is thought to contribute most to the efficacy of this antibody against malignant cells of B-cell lymphomas. 13, 14 Antibody-dependent cellular cytotoxicity is mediated by effector cells that engage the Fc portions of the antibody via receptors for immunoglobulin (Fc␥Rs). Three Fc␥R classes (Fc␥RI, Fc␥RII, and Fc␥RIII) and 8 subclasses have been described with significantly different haploptype distribution between various ethnic groups. [15] [16] [17] Fc␥RIIIa (CD16a) is expressed on natural killer cells and macrophages, whereas Fc␥RIIa (CD32a) is expressed on neutrophils and macrophages. Genomic polymorphism of the Fc␥RIIIA corresponding to phenotypic expression of valine (V: guu/guc/gua/gug) or phenylalanine (F: uuc/ uuu) at position 158 influences the binding of IgG 1 to this receptor. 18 It has been shown that natural killer cells with valine homozygous receptors (V/V) bind Fc better than those with phenylalanine receptors (F/F), resulting in more effective antibodydependent cellular cytotoxicity. 19 Patients with follicular lymphoma 20, 21 and Waldenström macroglobulinemia, 22 but not with CLL 23 carrying the Fc␥RIIIa 158 V/V phenotype, have been reported to respond better to rituximab monotherapy than F carriers, but this was not observed when rituximab was combined with CHOP. [24] [25] [26] With respect to Fc␥RIIa, patients with follicular lymphoma and homozygous for histidine (H: cau/cuc) on position 131 were reported to respond better to rituximab monotherapy than patients heterozygous or homozygous for arginine (R: cgu/cgc/cga/ cgg). 21 However, this observation could not be confirmed by others. 20, 23, 24, 27 With respect to DLBCL, the response of 85 Korean patients treated with CHOP was the same among the carriers of different Fc␥RIIIa polymorphisms; but among 113 patients treated with R-CHOP, carriers of the Fc␥RIIIa 158 V/V were reported to respond better than F carriers to R-CHOP. However, this was not confirmed in a small series of 58 white patients. 28 To evaluate, to the best of our knowledge, for the first time the role of Fc␥RIIa and Fc␥RIIIa polymorphisms on outcome of DLBCL patients who were treated uniformly within a prospective trial, where patients were randomly assigned to CHOP chemotherapy with and without rituximab, we examined the correlation of Fc␥RIIIa 158 V/F and Fc␥RIIa 131 H/R polymorphisms in patients treated within the RICOVER-60 study, 4 with 1222 patients, the largest DLBCL study to date. In this trial, patients had been randomized into 4 arms: 6 and 8 cycles of biweekly CHOP (CHOP-14), each with and without 8 applications of rituximab.
Methods
This study was approved by the local ethics committee, the Ethikkommission der Ä rztekammer des Saarlandes. The study was performed in accordance with the rules of the Declaration of Helsinki after obtaining written consent from the patients. Recombinant experiments were done The online version of this article contains a data supplement.
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with the permission and according to the rules of the government of Saarland.
Study population
The cohort consisted of 512 consecutive patients treated within the RICOVER-60 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (registered on National Cancer Institute website, no. CT0052936 and as EU-20243) from whom genomic DNA samples were available. All patients had untreated CD20 ϩ aggressive B-cell lymphoma according to the World Health Organization classification 29 as confirmed by reference pathology. Blood donors (n ϭ 101) from the Institute for Transfusion Medicine, Saarland University Medical School served as controls.
DNA extraction and genotyping
Genomic DNA was isolated from whole blood with the QIAamp DNA Blood Kit (QIAGEN). DNA was diluted in water to a final concentration of 5 ng/L to use 2.25 L per reaction. The mutation tests were performed using the TaqMan (Invitrogen) SNP Genotyping Assays C_258156666_10 for the detection of the polymorphism rs396991 for the Fc-␥ receptor IIIa (CD16a) and C_9077561_20 for the detection of the polymorphism rs1801274 of the low-affinity Fc-␥-IIa (CD32a) receptor, respectively. A total of 2.25 L genomic DNA was mixed with 2.5 L TaqMan Universal Maser Mix and 0.25 L TaqMan SNP Genotyping Assay Mix. After an initial denaturation at 95°C for 10 minutes, amplification was performed using 40 cycles of denaturation (92°C, 15 seconds), annealing (60°C, 1 minute), and extension (60°C, 1 minute). The PCR was performed using the Real-Time PCR StepOnePlus (Invitrogen).
Statistical analysis
Of the 1222 patients of the RICOVER-60 trial, DNA samples were available from 512. The allelic frequencies between lymphoma samples and controls were compared with Fisher exact test. Response was defined as the proportion of patients with complete remission or unconfirmed complete remission after study treatment for all patients evaluable for response. Response was assessed by use of Fisher exact test and Armitage trend test. 30 Event-free survival (EFS) was defined as the time from the beginning of therapy to disease progression, relapse, death, or initiation of additional (off-protocol) or salvage therapy. Progression-free survival (PFS) was defined as time to disease progression, relapse, or death. Overall survival (OS) was defined as time to death for any reason. EFS, PFS, and OS were estimated with the Kaplan-Meier method and were compared using the log-rank test. Kaplan-Meier estimates at 3 years (with 95% confidence interval [CI]) were calculated for the probability of not having an event in the endpoints of EFS, PFS, and OS. Multivariate analyses were done using Cox proportional-hazard models to estimate hazard ratios for having an event. Differences between groups were regarded as significant for P values Ͻ .05 (2-sided). Statistical analyses were performed with R Version 2.9 31
Results
The results of the RICOVER-60 trial have been published previously. In a 2 ϫ 2 randomized trial design, patients were randomized to 6 cycles of CHOP-14, 8 cycles of CHOP-14 without rituximab, or the same regimens plus 8 applications of rituximab every 2 weeks. The 2 arms with rituximab had a significantly improved EFS and PFS compared with 6 times CHOP-14 (P Ͻ .001), whereas only 6 cycles with 8 applications of rituximab, but not 8 cycles of CHOP-14 with 8 applications of rituximab, had a significantly improved OS compared with CHOP-14 (P ϭ .018 and P ϭ .260, respectively). The adherence to protocol was excellent: median relative doses for the myelosuppressive drugs were 98% or more (range, 1-118) for the 6-cycle regimens and 95% or more (range, 7-111) for the 8-cycle regimens, and median duration of chemotherapy cycles was 14 days (range, 8-92 days) in all regimens and cycles.
Prevalence of Fc␥RIIa and Fc␥RIIIa genotypes
Of 1222 elderly patients (61-80 years of age) recruited to the RICOVER-60 trial, samples for single nucleotide polymorphism (SNP) analysis were available from 512: 263 treated with R-CHOP-14 and 249 treated with CHOP-14 only. Their characteristics are shown in Table 1 and supplemental Tables 1 and 2 (available on the Blood Web site; see the Supplemental Materials link at the top of the online article). Except for a somewhat longer follow-up, these patients were representative of the entire RICOVER-60 population (supplemental Table 3 ). Among the 512 patients, 64 (12.5%) were carriers of Fc␥RIIa 131 R/R, 235 (45.9%) of R/H, and 213 (41.6%) of H/H. With respect to Fc␥RIIIa 158 polymorphism, the distribution was: V/V, 145 (28.3%); V/F, 271 (52.9%); and F/F, 96 (18.8%). The observed genotype frequencies did not deviate from those expected under the HardyWeinberg equilibrium. The genotypes of Fc␥RIIa 131 and Fc␥RIIIa 158 were only weakly linked (R 2 ϭ 0.026). The characteristics of patients from whom DNA was available for this study were not different for patients treated with R-CHOP and CHOP, respectively (supplemental Tables 1 and 2) . Similarly, the genotype frequencies were similar for both treatment arms (supplemental Table 4 ). In the groups treated with CHOP, there was an imbalance with respect to bulky disease for the Fc␥RIIa polymorphism: R/R had 27%, R/H 54%, and H/H 34% (P ϭ .003). In addition, there was a slight imbalance for the Fc␥RIIIa polymorphisms concerning Table 1 ) but not in the groups with R-CHOP. There were no significant differences between the Fc␥RIIa and Fc␥RIIIa polymorphisms in the groups treated with rituximab (supplemental Table 2 ). Given the large number of statistical tests in supplemental Tables 1 and 2 
infections was not different between the Fc␥RIIa and Fc␥RIIIa
SNPs (data not shown). The rate of therapy-associated deaths was 10.9% (4.5%-21.2%) for Fc␥RIIa 131 R/R, 5.5% (3.0%-9.3%) for Fc␥RIIa 131 R/H, and 5.2% (2.6%-9.1%) for H/H (P ϭ .220). There were no differences in therapy-associated deaths between the Fc␥RIIIa SNPs.
Response to therapy and outcome
The observation time was the same for all Fc␥RIIa and Fc␥RIIIa variants. The rates of complete remissions were not different between carriers of the Fc␥RIIa variants. With respect to the Table 2) .
EFS, PFS, and OS, according to the Fc␥RIIa and Fc␥RIIIa genotypes for the patients receiving CHOP-14 and R-CHOP-14, respectively, are shown in Figures 1 and 2 , and the number of events in the various subgroups is shown in supplemental Table 5 . The adherence to protocol was excellent, with relative doses of the myelotoxic drugs cyclophosphamide and doxorubicin being 98% in the 6-cycle arms and 96% in the 8-cycles arms. There were no differences between Fc␥R polymorphisms. Similarly, there were also no differences with respect to the percentage of patients going off therapy or receiving nonprotocol therapy (data not shown). For patients receiving CHOP-14 (Figure 1) , the survival curves of all SNPs were virtually superimposable. The survival curves according to the SNPs after R-CHOP-14 are shown in Figure 2 . The survival curves were not different with respect to Fc␥RIIa variants, whether treated with R-CHOP or CHOP, respectively. In contrast, although there was also no difference of the survival curves with respect to Fc␥RIIIa variants for patients treated with CHOP, in patients treated with R-CHOP, the EFS and PFS, but not the OS, curves for Fc␥RIIIa 158 F/F showed a trend to be lower than those of 158 V/F and 158 V/V. The 3-year EFS rates for Fc␥RIIIa 158 F/F were 64.5% (50.5%-78.5%), compared with 70.2% (62.5%-78.0%) for Fc␥RIIIa 158 V/F and 76.9% (67.3%-86.6%) for Fc␥RIIIa 158 V/V (log-rank test, P ϭ .224 for F/F vs V/V; P ϭ .285 for F/F vs V/F ϩ V/V). For 3-year PFS, the rates were 68.3% (54.6%-82.1%) for Fc␥RIIIa 158 F/F, compared with 76.1% (68.7%-83.5%) for Fc␥RIIIa 158 V/F and 80.5% (71.2%-89.7%) for Fc␥RIIIa 158 V/V (log-rank test, P ϭ .233; for F/F vs V/V; P ϭ .185 for F/F vs V/F ϩ V/V).
Multivariate analysis
Based on the results of the univariate analysis, we analyzed the impact of Fc␥RIIIa 158 in the R-CHOP cohort using a multivariate Cox model with adjustment for International Prognostic Index factors. Comparing F/F versus V/F plus V/V, the relative risk for PFS was 1.80 (P ϭ .052) for EFS 1.55 (P ϭ .120) and 1.35 (P ϭ .360) for OS. The results of the multivariate analysis within the R-CHOP cohort are shown in Table 3 . To further investigate the interaction between rituximab and the Fc␥RIIIa 158 SNP, we used the complete dataset to fit a Cox model adjusting for rituximab, Fc␥RIIIa 158, and the interaction between both. The observed relative risks for the interaction were 1.57 (P ϭ .24) for PFS, 1.47 (P ϭ .28) for EFS, and 1.01 for OS (Table 4) . Although not significant, these analyses indicate a trend toward an unfavorable outcome for carriers of Fc␥RIIIa 158 F/F under R-CHOP therapy. Given the observed effect sizes for the univariate analysis of the Fc␥RIIIa 158 SNP within the R-CHOP cohort, a post-hoc power analysis results in a power of 28% for PFS and 21% for EFS for the sample size of our R-CHOP cohort (n ϭ 263). For a power of 80%, a sample size of n ϭ 1100 (PFS) or n ϭ 1600 (EFS) would be needed.
Discussion
Fc␥R polymorphisms were not associated with clinical features presented by patients with DLBCL, except for B-symptoms, which were less often present in patients carrying Fc␥RIIIa 158 V/V (P ϭ .037). This observation, however, should be interpreted with caution because multiple clinical parameters were tested for association with Fc␥R polymorphisms, and thus, this association might have been observed by chance.
The focus of our study was to search for interactions between Fc␥R polymorphisms and outcome of patients treated with R-CHOP. It has been suggested that the level of CD20 expression on lymphoma cells, 32 the presence of high tumor burden at the time of treatment, 33 or low rituximab serum concentrations 32, 34 may explain the lack of efficacy of rituximab in some patients. Nevertheless, the actual causes of treatment failure are largely unknown. Cartron et al 20 were the first to show that polymorphisms in the Fc␥RIIIa gene were also associated with the response to therapy in patients with follicular lymphoma with rituximab monotherapy. This was confirmed by Weng and Levy 21 and was also observed by Ghielmini et al 35 in patients with Waldenström macroglobulinemia. 22 There are fewer reports showing a role of Fc␥RIIa polymorphisms. 21 To the best of our knowledge, there are only 2 publications on the role of Fc␥R polymorphisms in DLBCL: in a study of Korean patients, Fc␥IIIa, but not Fc␥IIa, polymorphisms were associated with outcome after R-CHOP, whereas a small European study did not observe any differences with respect to Fc␥R alleles. 28 Both studies suffer from relatively small numbers of patients included. Moreover, neither study restricted their analysis to patients treated uniformly within a prospective trial. This study is the first that is restricted to a single large prospective study, the RICOVER-60 trial. 4 Although no influence of Fc␥RIIa on outcome of patients treated with CHOP-14 or R-CHOP-14 was observed, Fc␥IIIa alleles had an interaction with outcome after R-CHOP, but not CHOP, with Fc␥IIIa F/F being associated with a trend toward an inferior CR rate, EFS, and PFS. Despite the fact that this is by far the largest study on the role of Fc␥R polymorphisms in DLBCL, the differences between the different Fc␥RIIIa alleles did not reach significance. An extrapolation modeling showed that this would also not have been the case if blood samples of all 1222 DLBCL patients treated in the RICOVER-60 trial had been available: for a power of 80%, a sample size of 1100 patients for PFS and 1600 patients for EFS would have been needed. Nevertheless, the interaction between Fc␥IIIa and R-CHOP was relevant for PFS and EFS. The observed relative risks for the interaction were 1.57 (P ϭ .24) for PFS and 1.47 (P ϭ .28) for EFS (Table 4) . Although not significant, these analyses indicate a trend toward an unfavorable outcome for carriers of Fc␥RIIIa 158 F/F under R-CHOP therapy. Although a similar trend was reported in R-CHOP-treated patients in the Korean study, the differences in outcome in our study with respect to Fc␥IIIa polymorphisms did not reach significance, despite the much higher number of patients included in this study. This might be because the Korean patients were treated with a thrice-weekly regimen and our patients with a twice-weekly application of rituximab. The higher rituximab serum levels achieved with the biweekly application (C. Müller, N. Murawski, G. Held, M. Wiesen, M. Wenger, C. Nickenig, N. Peter, E. Lengfelder, B. Metzner, M.P., and M. Reiser, Differences in rituximab clearance and serum elimination half life between elderly male and female patients with DLBCL, manuscript under review) might quench possible differences between Fc receptors with different binding affinities to rituximab; however, the interaction of the different pharmacokinetics of the twice-weekly and thrice-weekly application of rituximab and Fc␥R polymorphisms is unknown. Therefore, the differences between our study in white patients and the Korean study might be the result of other reasons (eg, other yet unidentified genetic differences). When one looks at studies that investigated Fc␥R polymorphisms in patients treated with monoclonal antibodies, it becomes evident that interactions between Fc␥IIIa polymorphisms and outcome have been observed repeatedly, even if antibody therapy was combined with chemotherapy. For Fc␥RIIa polymorphisms, this was not reported when the respective antibody was combined with cytotoxic agents.
In conclusion, we found a relevant interaction for Fc␥IIIa receptor polymorphisms with R-CHOP, but not with CHOP, treatment in this largest series of DLBCL patients treated uniformly within the randomized RICOVER-60 trial. Whether this relevant interaction translates into significant differences in outcome of patients with different Fc␥IIIa polymorphisms depends (in addition to the number of patients studied) on many factors, only some of which have been identified. The interaction between Fc␥IIIA receptor polymorphisms and rituximab, even when combined with CHOP chemotherapy, provides a more or less opened window of opportunity for therapeutic monoclonal antibodies engineered to overcome the differences in binding of their Fc parts to Fc␥RIIIa coded by distinct polymorphisms. [36] [37] [38] 
